Human albumin in the management of complications of liver cirrhosis

Critical Care

Volumn 16, Issue 2, 2012, Pages

  Bernardi, Mauro ^a   Maggioli, Caterina ^b   Zaccherini, Giacomo ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HUMAN SERUM ALBUMIN; MIDODRINE; NORADRENALIN; OCTREOTIDE; TERLIPRESSIN; ALBUMINOID; SERUM ALBUMIN;

ASCITES; BACTERIAL PERITONITIS; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; PARACENTESIS; PLASMA VOLUME; PRIORITY JOURNAL; REVIEW; COMPLICATION; LIVER FUNCTION TEST; METABOLISM;

ALBUMINS; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; SERUM ALBUMIN;

EID: 84857670937     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11218     Document Type: Review

References (39)

1. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005, 41:1211-1219. 10.1002/hep.20720, 15915465.
2. Mirici-Cappa F, Caraceni P, Domenicali M, et al. How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol 2011, 17:3479-3486. 10.3748/wjg.v17.i30.3479, 3163245, 21941414.
3. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, . SAFE Study Investigators A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350:2247-2256. SAFE Study Investigators.
4. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011, 39:386-391. 10.1097/CCM.0b013e3181ffe217, 21248514.
5. Vincent JL. Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol 2009, 23:183-191. 10.1016/j.bpa.2008.11.004, 19653438.
6. Evans TW. Review article: albumin as a drug. Biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002, 16:S6-S11.
7. Oettl K, Stauber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007, 151:580-590. 10.1038/sj.bjp.0707251, 2013999, 17471184.
8. Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006, 47:493-502. 10.1053/j.ajkd.2005.11.026, 16490629.
9. Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G, . OPERA Investigators Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J 2010, 159:570-576. 10.1016/j.ahj.2009.12.026, 20362714, OPERA Investigators.
10. Henricksen JH, Siemssen O, Krintel JJ, Malchow-Møller A, Bendtsen F, Ring-Larsen H. Dynamics of albumin in plasma and acitic fluid in patients with cirrhosis. J Hepatol 2001, 34:53-60.
11. Wood LJ, Colman J, Dudley FJ. The relationship between portal pressure and plasma albumin in the development of cirrhotic ascites. J Gastroenterol Hepatol 1987, 2:525-531.
12. Rector WG, Ibarra F, Openshaw K, Hoefs JC. Ascites kinetics in cirrhosis: relationship to plasma-ascites hydrostatic-oncotic balance and intensity of renal sodium retention. J Lab Clin Med 1986, 107:412-419.
13. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008, 57:268-278. 10.1136/gut.2006.112177, 18192456.
14. Ginés P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1998, 94:1493-1502.
15. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409. 10.1056/NEJM199908053410603, 10432325.
16. Martín-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008, 134:1352-1359. 10.1053/j.gastro.2008.02.024, 18471512.
17. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134:1360-1368.
18. Ginès A, Fernandez-Esparrach G, Monescillo A, et al. Randomized controlled trial comparing albumin, dextran-70 and polygelin in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111:1002-1010.
19. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010, 53:397-417. European Association for the Study of the Liver.
20. Moreau R, Valla DC, Durand-Zaleski I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006, 26:46-54. 10.1111/j.1478-3231.2005.01188.x, 16420509.
21. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007, 56:1310-1318. 1954971, 17389705.
22. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009, 361:1279-1290. 10.1056/NEJMra0809139, 19776409.
23. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of prospective, non-randomized study. Hepatology 2002, 36:941-948.
24. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010, 51:576-584. 10.1002/hep.23286, 19885875.
25. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology 1999, 29:1690-1697. 10.1002/hep.510290629, 10347109.
26. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007, 47:499-505. 10.1016/j.jhep.2007.04.010, 17560680.
27. Caraceni P, Santi L, Mirici F, et al. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis 2011, 43:242-245. 10.1016/j.dld.2010.08.001, 20833118.
28. Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007, 56:597-599. 10.1136/gut.2006.113050, 1856861, 17369392.
29. Fernández J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005, 42:627-634. 10.1002/hep.20829, 16108036.
30. Clermont RJ, Vlahevic ZR, Chalmers TC, Adham NF, Curtis GW, Morrosin RS. Intravenous therapy of massive ascites in patients with cirrhosis. Long-term effects on survival and frequency of renal failure. Gastroenterology 1967, 53:220-228.
31. Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999, 30:639-645. 10.1016/S0168-8278(99)80194-9, 10207805.
32. Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006, 12:1403-1407.
33. Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S. Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 2004, 20:351-357. 10.1016/j.nut.2003.12.006, 15043850.
34. Oettl K, Stadlbauer V, Petter F, et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008, 1782:469-473.
35. Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009, 50:555-564.
36. Oettl K, Stadlbauer V, Krisper P, Stauber RE. Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure. Ther Apher Dial 2009, 13:431-436. 10.1111/j.1744-9987.2009.00762.x, 19788461.
37. Karvellas CJ, Gibney N, Kutsogiannis D, Wendon J, Bain VG. Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care 2007, 11:215. 10.1186/cc5922, 2206413, 17567927.
38. Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, . Relief Study Group Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF Trial. J Hepatol 2010, 52:S459-S460. Relief Study Group.
39. Rifai K, Kribben A, Gerken G, et al. Extracorporeal liver support by fractionated plasma separation and adsorption (PROMETHEUS) in patients with acute-on-chronic liver failure (HELIOS Study): a prospective randomized controlled multicenter study. J Hepatol 2010, 52:S3.